10 Jan 2024
Senior executives of ZERO Biotech signed a Memorandum of Understanding (MoU) with Xi'an Jiaotong University, a leading academic institution in medicine research and development in China. The MoU signifies a strategic partnership aimed at licensing a novel molecule developed at the University to ZERO Biotech, enabling further drug development and potential commercialization.
The collaboration between ZERO Biotech and Xi'an Jiaotong University represents a significant milestone in advancing the promising field of drug development. The novel molecule, concerned in this agreement with undisclosed details, has shown promising results in preclinical studies, demonstrating immense potential in therapeutic efficacy.
Under the terms of the MoU, ZERO Biotech will obtain exclusive licensing rights to further develop and commercialize the novel molecule for diagnostic and therapeutic applications in nuclear medicine. The molecule's innovative properties have the potential to revolutionize the treatment landscape for various diseases, addressing unmet medical needs and improving patient outcomes.
The current novel radiopharmaceuticals development is mainly dominant in the west. ZERO Biotech being the nuclear medicine player in Asia, enjoys the benefits of partnering with renowned research institutes in Asia, and conducting clinical trials in Asia for Asian patients.
ZERO Biotech has been identifying research partners in China and Asia.
Xi'an Jiaotong University, known for its excellence in scientific research and academic achievements, has a proven track record of fostering innovation and nurturing intellectual talent. The university's commitment to advancing scientific knowledge and translating research findings into real-world applications makes it an ideal partner for ZERO Biotech's drug development initiatives.
ZERO Biotech's collaboration with Xi'an Jiaotong University reinforces its commitment to identifying and harnessing cutting-edge scientific advancements to address critical medical challenges. By combining the strengths of academia and industry, this partnership has the potential to bring transformative therapies to the market and significantly impact global healthcare.